Cecile Grootscholten
- Nephrology top 2%
- Renal Diseases and Glomerulopathies 8
- Rheumatology top 2%
- Systemic Lupus Erythematosus Research 13
- Gastroenterology top 5%
- Hepatology top 5%
- Liver Diseases and Immunity 6
- Immunology top 10%
-
- Gastric Cancer Management and Outcomes 18
- Metastasis and carcinoma case studies 5
-
- Esophageal Cancer Research and Treatment 13
-
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 8
- Co-authors
- Jo H. M. BerdenJack SatsangiD P JewellHelen HoltMarc BijlHans C. van HouwelingenJohanna W. van SandickRonald H. W. M. Derksen
- Partner nations
- NetherlandsUnited StatesGermany
In The Last Decade
Cecile Grootscholten
51 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 85
- Nephrology 289
- Rheumatology 563
- Gastroenterology 108
- Hepatology 154
- Immunology 362
Countries citing papers authored by Cecile Grootscholten
This map shows the geographic impact of Cecile Grootscholten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cecile Grootscholten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cecile Grootscholten more than expected).
Fields of papers citing papers by Cecile Grootscholten
This network shows the impact of papers produced by Cecile Grootscholten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cecile Grootscholten. The network helps show where Cecile Grootscholten may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Cecile Grootscholten, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trialbreakdown → | 2024 | 40 |
| 2 | 2024 | 1 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 4 | |
| 5 | 2021 | 57 | |
| 6 | 2021 | 14 | |
| 7 | 2021 | 5 | |
| 8 | 2020 | 35 | |
| 9 | 2020 | 8 | |
| 10 | 2020 | 1 | |
| 11 | 2020 | 31 | |
| 12 | 2020 | 37 | |
| 13 | 2018 | 46 | |
| 14 | 2018 | 7 | |
| 15 | 2017 | 13 | |
| 16 | 2017 | 1 | |
| 17 | 2017 | 28 | |
| 18 | Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis. | 2014 | 9 |
| 19 | 2011 | 49 | |
| 20 | 2006 | 21 |
About Cecile Grootscholten
Cecile Grootscholten is a scholar working on Nephrology, Hepatology and Gastroenterology, having authored 52 papers that have together received 1.4k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (18 papers), Esophageal Cancer Research and Treatment (13 papers), Systemic Lupus Erythematosus Research (13 papers), Cancer Immunotherapy and Biomarkers (10 papers), Colorectal Cancer Treatments and Studies (8 papers), Renal Diseases and Glomerulopathies (8 papers), Liver Diseases and Immunity (6 papers) and Metastasis and carcinoma case studies (5 papers). The work is most often cited by research in Nephrology (289 citations), Rheumatology (563 citations) and Gastroenterology (108 citations). Cecile Grootscholten has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Jo H. M. Berden, Jack Satsangi, D P Jewell, Helen Holt, Marc Bijl, Hans C. van Houwelingen, Johanna W. van Sandick, Ronald H. W. M. Derksen, R. H. W. M. Derksen and Johan van der Vlag. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.